Clinical Trial Update: Flupenthixol Decanoate in Methamphetamine Smoking - 1 [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating flupenthixol decanoate for methamphetamine smoking in individuals with substance-related disorders has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Substance-related Disorders

Drugs mentioned

• Flupenthixol Decanoate (Flupenthixol decanoate)

Snippet

Sponsor: National Institute on Drug Abuse (NIDA) | Conditions: Substance-Related Disorders | Phase 2 | Status: COMPLETED